KYODO NEWS IMAGELINK

報道写真の購入なら共同通信イメージズ

  • 新型肺炎
  • ドイツ
  • 新型コロナウイルス感染症
  • 厚労省
  • マスク
  • 期待
  • ぜんそく
  • 令和
  • 作業
  • 医療

「レムデシビル」の写真・グラフィックス・映像

絞り込み
  • 提供元
  • 日付
  • 種類
  • 向き
  • カテゴリ
並び順
  • 古い順
150
( 1 100 件を表示)
  • 1
  • 2
150
( 1 100 件を表示)
絞り込み
並び順
  • 古い順
  • 2020年02月05日
    新型肺炎の抗ウイルス薬レムデシビル、武漢で臨床試験開始へ

    5日、プロジェクトの状況を説明する中国工程院副院長で中国医学科学院院長の王辰(おう・しん)院士(右から1人目)。中国科学技術部、国家衛生健康委員会、国家薬品監督管局などの多くの部門の支持の下、抗ウイルス薬物「レムデシビル(remdesivir)」はすでに臨床試験の登録審査・認可の作業を終え、第1陣の症例登録もすでに始まった。新型コロナウイルス感染による肺炎の重症患者に6日に投薬される。(武漢=新華社記者/程敏)=2020(令和2)年2月5日、クレジット:新華社/共同通信イメージズ

    商品コード: 2020020609649

  • 2020年02月05日
    新型肺炎の抗ウイルス薬レムデシビル、武漢で臨床試験開始へ

    5日、レムデシビル臨床試験プロジェクトの内容を説明する同プロジェクト責任者で中日友好病院副院長の曹彬(そう・ひん)教授。中国科学技術部、国家衛生健康委員会、国家薬品監督管局などの多くの部門の支持の下、抗ウイルス薬物「レムデシビル(remdesivir)」はすでに臨床試験の登録審査・認可の作業を終え、第1陣の症例登録もすでに始まった。新型コロナウイルス感染による肺炎の重症患者に6日に投薬される。(武漢=新華社記者/程敏)=2020(令和2)年2月5日、クレジット:新華社/共同通信イメージズ

    商品コード: 2020020609687

  • 2020年03月11日
    World News - March 11, 2020

    March 11, 2020: A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States in this March 2020 photo provided by Gilead Sciences. (Credit Image: © Ho/The Canadian Press via ZUMA Press)、クレジット:©Ho/The Canadian Press via ZUMA Press/共同通信イメージズ ※Canada and U.S. RIGHTS OUT

    商品コード: 2020073104134

  • 2020年03月11日
    World News - March 11, 2020

    March 11, 2020: A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States in this March 2020 photo provided by Gilead Sciences. Health Canada has approved the use of remdesivir to treat patients with severe symptoms of COVID-19. The federal agency says the antiviral drug may be used to treat patients who have pneumonia and require extra oxygen to help them breathe. (Credit Image: © Ho/The Canadian Press via ZUMA Press)、クレジット:©Ho/The Canadian Press via ZUMA Press/共同通信イメージズ ※Canada and U.S. RIGHTS OUT

    商品コード: 2020073100862

  • 2020年03月19日
    抗HIV薬、ぜんそく薬…

    新型コロナウイルス感染症に効果が期待される既存薬

    商品コード: 2020031922672

  • 2020年03月19日
    抗HIV薬、ぜんそく薬…

    新型コロナウイルス感染症に効果が期待される既存薬

    商品コード: 2020031922675

  • 2020年03月24日
    Martin Balik

    Doctor Martin Balik of the General Teaching Hospital in Prague speaks during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020032513223

  • 2020年03月24日
    David Feltl

    Director of the General Teaching Hospital in Prague David Feltl speaks during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020032513261

  • 2020年03月24日
    Martin Balik, David Feltl

    Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020032512896

  • 2020年03月27日
    Martin Balik

    Doctor Martin Balik of the General Teaching Hospital in Prague speaks during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020033105172

  • 2020年03月27日
    Martin Balik, David Feltl

    Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020033105152

  • 2020年03月27日
    Martin Balik, David Feltl

    Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020033105163

  • 2020年03月27日
    Martin Balik, David Feltl

    Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020033105158

  • 2020年03月27日
    Martin Balik, David Feltl

    Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020033105159

  • 2020年03月27日
    Martin Balik, David Feltl

    Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020033105157

  • 2020年03月27日
    David Feltl

    Director of the General Teaching Hospital in Prague David Feltl speaks during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020033105167

  • 2020年04月03日
    Martin Balik, David Feltl

    The General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020040800420

  • 2020年04月03日
    Martin Balik, David Feltl

    The General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020040800379

  • 2020年04月03日
    Martin Balik, David Feltl

    The General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020040800409

  • 2020年04月03日
    Martin Balik, David Feltl

    The General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020040800373

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: An ampoule of the drug Remdesivir is on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000960

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: Two ampoules of the drug Remdesivir are on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000961

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, talks to the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000971

  • 2020年04月08日
    Corona drug Remdesivir

    FILED - 08 April 2020, Hamburg: An ampoule of the drug Remdesivir is on the table during a press conference at the University Hospital Eppendorf (UKE). The EU Commission has concluded a supply contract with the manufacturer Gilead to supply 30,000 seriously ill Covid-19 patients with the drug Remdesivir. The active ingredient - the only drug approved in Europe to date for severe cases of coronavirus-induced lung disease - will be supplied from the beginning of August, the Brussels authorities announced on Wednesday. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020073105809

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, holds ampoules of the drug Remdesivir in her hands during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000967

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The head of the Institute for Transfusion Medicine, Dr. Sven Peine, answers the questions of the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041001022

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The director of the Department of Intensive Care Medicine, Prof. Dr. Stefan Kluge (l-r), the head of Infectiology, Prof. Dr. Marylyn Addo, and the head of the Institute of Transfusion Medicine, Dr. Sven Peine, answered the journalists‘ questions during a press conference at the University Hospital Eppendorf (UKE). They informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000945

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: An ampoule of the drug Remdesivir is lying on one hand during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000985

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The director of the Department of Intensive Care Medicine, Prof. Dr. Stefan Kluge (l-r), the head of Infectiology, Prof. Dr. Marylyn Addo, and the head of the Institute of Transfusion Medicine, Dr. Sven Peine, answered the journalists‘ questions during a press conference at the University Hospital Eppendorf (UKE). They informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000998

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, talks to the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041001003

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The director of the Department of Intensive Care Medicine, Prof. Dr. Stefan Kluge, will answer the journalists‘ questions during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041001016

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    dpatop - 08 April 2020, Hamburg: An ampoule of the drug Remdesivir is on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041001101

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, talks to the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041001001

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, talks to the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000964

  • 2020年04月08日
    Coronavirus - Study start at the UKE with Ebola drug Remdesivir

    08 April 2020, Hamburg: Two ampoules of the drug Remdesivir are on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020041000980

  • 2020年04月10日
    レムデシビル 進む既存薬試験、新薬開発

    エボラ出血熱の治療薬候補「レムデシビル」(ロイター=共同)

    商品コード: 2020041002488

  • 2020年04月11日
    レムデシビル エボラ薬「見込みあり」

    新型コロナウイルス感染症の治療に期待されている抗ウイルス薬「レムデシビル」(ロイター=共同)

    商品コード: 2020041101360

  • 2020年04月30日
    レムデシビル コロナ薬効果、米中で違い

    新型コロナウイルス感染症の治療薬候補「レムデシビル」(ロイター=共同)

    商品コード: 2020043000066

  • 2020年05月02日
    トランプ大統領 米、レムデシビル投与許可

    ホワイトハウスの執務室で「レムデシビル」を開発した米製薬企業ギリアド・サイエンシズの幹部と面会するトランプ米大統領(右)=1日(ゲッティ=共同)

    商品コード: 2020050200084

  • 2020年05月02日
    レムデシビル 早期承認に向け閣議決定

    米製薬会社ギリアド・サイエンシズが開発した新型コロナウイルス感染症の治療候補薬レムデシビル(ロイター=共同)

    商品コード: 2020050200393

  • 2020年05月02日
    厚労相「1週間で承認」

    商品コード: 2020050200409-3

  • 2020年05月02日
    厚労相「1週間で承認」

    商品コード: 2020050200409-1

  • 2020年05月02日
    厚労相「1週間で承認」

    商品コード: 2020050200409-4

  • 2020年05月02日
    厚労相「1週間で承認」

    商品コード: 2020050200409-2

  • 2020年05月02日
    取材に応じる加藤厚労相 厚労相「1週間で承認」

    新型コロナウイルスの治療候補薬レムデシビルの特例承認について話す加藤厚労相=2日午後、厚労省

    商品コード: 2020050200409

  • 2020年05月02日
    取材に応じる加藤厚労相 厚労相「1週間で承認」

    新型コロナウイルスの治療候補薬レムデシビルの特例承認について話す加藤厚労相=2日午後、厚労省

    商品コード: 2020050200408

  • 2020年05月05日
    Robert Markovic, David Feltl

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (left), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. On the right side is seen director of the hospital David Feltl. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101491

  • 2020年05月05日
    Robert Markovic

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101499

  • 2020年05月05日
    Robert Markovic

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101501

  • 2020年05月05日
    Robert Markovic

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101384

  • 2020年05月05日
    Robert Markovic

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101393

  • 2020年05月05日
    Robert Markovic

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101394

  • 2020年05月05日
    Robert Markovic

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101415

  • 2020年05月05日
    Robert Markovic, Michal Sotola

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (left), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. On the right side is seen doctor Michal Sotola. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101398

  • 2020年05月05日
    Robert Markovic

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101409

  • 2020年05月05日
    Robert Markovic, Martin Balik

    The General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (left), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. On the right side is seen doctor Martin Balik. (CTK Photo/Michal Krumphanzl)、クレジット:CTK/共同通信イメージズ

    商品コード: 2020051101507

  • 2020年05月07日
    レムデシビル コロナ治療薬、初承認へ

    米製薬企業が開発した「レムデシビル」(ロイター=共同)

    商品コード: 2020050700914

  • 2020年05月07日
    コロナ治療に多数の候補薬

    新型コロナウイルス感染症の治療法として注目される薬の例

    商品コード: 2020050701279

  • 2020年05月07日
    コロナ治療に多数の候補薬

    新型コロナウイルス感染症の治療法として注目される薬の例

    商品コード: 2020050701278

  • 2020年05月07日
    コロナ治療に多数の候補薬

    新型コロナウイルス感染症の治療法として注目される薬の例

    商品コード: 2020050701281

  • 2020年05月07日
    コロナ治療に多数の候補薬

    新型コロナウイルス感染症の治療法として注目される薬の例

    商品コード: 2020050701283

  • 2020年05月07日
    取材に応じる加藤厚労相 コロナ治療薬、国が初承認

    新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認し、取材に応じる加藤厚労相=7日午後9時59分、厚労省

    商品コード: 2020050702285

  • 2020年05月07日
    レムデシビルの使用法

    レムデシビルの主な使用法や注意点

    商品コード: 2020050702329

  • 2020年05月07日
    レムデシビルの使用法

    レムデシビルの主な使用法や注意点

    商品コード: 2020050702332

  • 2020年05月07日
    レムデシビルの使用法

    レムデシビルの主な使用法や注意点

    商品コード: 2020050702334

  • 2020年05月07日
    レムデシビルの使用法

    レムデシビルの主な使用法や注意点

    商品コード: 2020050702336

  • 2020年05月07日
    発表する加藤厚労相 コロナ治療薬、国が初承認

    新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表する加藤厚労相=7日午後9時59分、厚労省

    商品コード: 2020050702342

  • 2020年05月07日
    質問に答える加藤厚労相 コロナ治療薬、国が初承認

    新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表し、取材に応じる加藤厚労相(中央)=7日午後10時2分、厚労省

    商品コード: 2020050702347

  • 2020年05月07日
    応じる加藤厚労相 コロナ治療薬、国が初承認

    新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表し、取材に応じる加藤厚労相=7日午後10時5分、厚労省

    商品コード: 2020050702370

  • 2020年05月07日
    答える加藤厚労相 コロナ治療薬、国が初承認

    新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表し、取材に応じる加藤厚労相=7日午後10時5分、厚労省

    商品コード: 2020050702378

  • 2020年05月07日
    取材対応する加藤厚労相 コロナ治療薬、国が初承認

    新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表し、取材に応じる加藤厚労相(中央奥)=7日午後10時2分、厚労省

    商品コード: 2020050702490

  • 2020年05月08日
    国内初のコロナ治療薬

    レムデシビルの特徴

    商品コード: 2020050805580

  • 2020年05月08日
    国内初のコロナ治療薬

    レムデシビルの特徴

    商品コード: 2020050805581

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107213

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107255

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: Samples for coronavirus research are placed on a table in the laboratory of the Heinrich Heine University in Düsseldorf. The research projects include immunity after cured infection and research data on the effectiveness and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107256

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107370

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107244

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107233

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107279

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107317

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107337

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A sign with the inscription “Genlabor S2“ sticks to a door. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107428

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107091

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107125

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107165

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107219

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: Samples for coronavirus research are placed on a table in the laboratory of the Heinrich Heine University in Düsseldorf. The research projects include immunity after cured infection and research data on the effectiveness and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107220

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107297

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107344

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107398

  • 2020年05月20日
    Coronavirus - Research in Düsseldorf

    20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020052107135

  • 2020年05月29日
    On remdesivir import On remdesivir import

    On remdesivir import Jung Eun-kyeong, head of the Korea Centers for Disease Control and Prevention (KCDC), listens to a reporter‘s question about a plan to import U.S. pharmaceutical giant Gilead Sciences Inc.‘s remdesivir as special treatment for COVID-19 patients during a regular briefing session at the KCDC headquarters in Cheongju, 137 kilometers south of Seoul, on May 29, 2020. (Yonhap)/2020-05-29 17:13:01/ < 1980-2020 YONHAPNEWS AGENCY. .> (Newscom TagID: yonphotos168300) [Photo via Newscom]、クレジット:YONHAPNEWS/ニューズコム/共同通信イメージズ

    商品コード: 2020060803401

  • 2020年06月03日
    Seoul approves remdesivir as virus treatment Seoul approves remdesivir as virus treatment

    Seoul approves remdesivir as virus treatment A medical worker checks bottles of the anti-viral drug remdesivir for patients infected with the new coronavirus at Seoul National University Hospital on June 3, 2020. South Korea the same day approved the use of the drug, developed by U.S. firm Gilead Sciences Inc., paving the way for the first inbound shipments of the new drug. (Yonhap)/2020-06-03 16:14:21/ < 1980-2020 YONHAPNEWS AGENCY. .> (Newscom TagID: yonphotos168598) [Photo via Newscom]、クレジット:YONHAPNEWS/ニューズコム/共同通信イメージズ

    商品コード: 2020061801874

  • 2020年06月29日
    COVID-19 medicine production in Egypt

    29 June 2020, Egypt, Giza: An employee of Egyptian pharmaceutical company Eva Pharma works on the production line of Remdesivir, a broad-spectrum antiviral medication which has been approved as a specific treatment for COVID-19. Eva Pharma started this week the production of Remdesivir with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020063005185

  • 2020年06月29日
    COVID-19 medicine production in Egypt

    29 June 2020, Egypt, Giza: An employee of Egyptian pharmaceutical company Eva Pharma holds a pack containing vials of Remdesivir, a broad-spectrum antiviral medication approved as a specific treatment for COVID-19, at the company‘s factory, which started producing the drug this week with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020063005264

  • 2020年06月29日
    COVID-19 medicine production in Egypt

    29 June 2020, Egypt, Giza: Employees of Egyptian pharmaceutical company Eva Pharma operate at the company‘s factory, where the production of Remdesivir, a broad-spectrum antiviral medication approved as a specific treatment for COVID-19, has started this week with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020063005322

  • 2020年06月29日
    COVID-19 medicine production in Egypt

    29 June 2020, Egypt, Giza: Employees of Egyptian pharmaceutical company Eva Pharma operate at the company‘s factory, where the production of Remdesivir, a broad-spectrum antiviral medication approved as a specific treatment for COVID-19, has started this week with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020063005459

  • 2020年06月29日
    COVID-19 medicine production in Egypt

    29 June 2020, Egypt, Giza: An employee of Egyptian pharmaceutical company Eva Pharma works on the production line of Remdesivir, a broad-spectrum antiviral medication which has been approved as a specific treatment for COVID-19. Eva Pharma started this week the production of Remdesivir with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020063005196

  • 2020年06月29日
    COVID-19 medicine production in Egypt

    29 June 2020, Egypt, Giza: Packs containing vials of Remdesivir, a broad-spectrum antiviral medication approved as a specific treatment for COVID-19, lie next to an employee of Egyptian pharmaceutical company Eva Pharma at the company‘s factory, which started producing the drug this week with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット:DPA/共同通信イメージズ

    商品コード: 2020063005255

  • 1
  • 2